Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 19/20 | 0.49 |
| ▸ | THRB | P10828 | 6/20 | 0.49 |
| ▸ | MAP3K20 | Q9NYL2 | 5/20 | 0.47 |
| ▸ | TGFBR2 | P37173 | 5/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18123893 | 1.00 | TGFBR1 (0.49) | TGFBR1THRBMAP3K20TGFBR2CYP2D6 | |
| SCHEMBL18115022 | 0.92 | TGFBR1 (0.50) | TGFBR1THRBMAP3K20TGFBR2CYP2D6 | |
| SCHEMBL29908573 | 0.92 | TGFBR1 (0.50) | TGFBR1THRBMAP3K20TGFBR2CYP2D6 | |
| SCHEMBL18124113 | 0.89 | THRB (0.46) | TGFBR1THRBMAP3K20TGFBR2CYP2D6 | |
| SCHEMBL29908575 | 0.89 | THRB (0.46) | TGFBR1THRBMAP3K20TGFBR2CYP2D6 | |
| SCHEMBL18115112 | 0.88 | TGFBR1 (0.53) | TGFBR1THRBMAP3K20TGFBR2CYP2D6 | |
| SCHEMBL29908601 | 0.88 | TGFBR1 (0.53) | TGFBR1THRBMAP3K20TGFBR2CYP2D6 | |
| SCHEMBL18114950 | 0.88 | TGFBR1 (0.48) | TGFBR1THRBMAP3K20TGFBR2CYP2D6 | |
| SCHEMBL29908600 | 0.88 | TGFBR1 (0.48) | TGFBR1THRBMAP3K20TGFBR2CYP2D6 | |
| SCHEMBL29908605 | 0.86 | THRB (0.53) | TGFBR1THRBMAP3K20TGFBR2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12227508-B2 | TGF-β inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-20230123591-A1 | TGF-ß INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-11466018-B2 | TGF-β inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2022-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12227508-B2 | TGF-β inhibitors | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885THRB 102/4885MAP3K20 1663/4885 |
| US-11466018-B2 | TGF-β inhibitors | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885THRB 102/4885MAP3K20 1663/4885 |
| US-20230123591-A1 | TGF-ß INHIBITORS | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885THRB 86/4885MAP3K20 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.